Standard Chemical & Pharmaceutical CoTPE:1720 95 Interest Coverage is 119.64 as of Dec. 2025, which is 36% above its 10-year median of 87.70. GuruFocus rates TPE:1720 with a GF Score™ of 95/100 and a GF Value™ of NT$70.93 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 685 Drug Manufacturers companies, Standard Chemical & Pharmaceutical Co ranks better than 83.94% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Standard Chemical & Pharmaceutical Co's
Operating Income
for the
three
months ended in Dec. 2025 was NT$353 Mil. Standard Chemical & Pharmaceutical Co's Interest Expense for the
three
months ended in Dec. 2025 was NT$-3 Mil.
Standard Chemical & Pharmaceutical Co's interest coverage for the quarter that ended in Dec. 2025 was 119.64.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Standard Chemical & Pharmaceutical Co Ltd has enough cash to cover all of its debt. Its financial situation is stable.
TPE:1720'
s Interest Coverage Range Over the Past 10 Years
Min: 44.28 Med: 87.7 Max: 161.01
Current: 161.01
TPE:1720's Interest Coverage is ranked better than 83.94% of 685
companies
in the Drug Manufacturers industry
Industry Median: 12.75
vs TPE:1720: 161.01
Standard Chemical & Pharmaceutical Co (TPE:1720) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Standard Chemical & Pharmaceutical Co Interest Coverage Related Terms
Standard Chemical & Pharmaceutical Co Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Standard Chemical & Pharmaceutical Co Interest Coverage Chart
TPE:1720 vs ZTS, UTHR: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Standard Chemical & Pharmaceutical Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Standard Chemical & Pharmaceutical Co Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Standard Chemical & Pharmaceutical Co's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Standard Chemical & Pharmaceutical Co's Interest Coverage falls into.
Standard Chemical & Pharmaceutical Co Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Standard Chemical & Pharmaceutical Co (TPE:1720) has a Interest Coverage of 119.64 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Standard Chemical & Pharmaceutical Co and its competitors. This is 36% above median its historical median of 87.70. Over the past decade, Standard Chemical & Pharmaceutical Co's Interest Coverage has ranged from 44.28 to 161.01. According to the industry distribution chart, Standard Chemical & Pharmaceutical Co ranks #110 out of 685 companies in the Drug Manufacturers industry, placing it in the top 16.1%.
Is Standard Chemical & Pharmaceutical Co's Interest Coverage too high?
Standard Chemical & Pharmaceutical Co's current Interest Coverage of 119.64 is 36% above median its 10-year median of 87.70. Over the past 10 years, this metric has ranged from a low of 44.28 to a high of 161.01. The Drug Manufacturers industry median Interest Coverage is 12.75. Standard Chemical & Pharmaceutical Co's value of 119.64 is 838.4% above this industry median. Based on the distribution chart, Standard Chemical & Pharmaceutical Co ranks #110 out of 685 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Standard Chemical & Pharmaceutical Co has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Standard Chemical & Pharmaceutical Co's Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Standard Chemical & Pharmaceutical Co ranks #110 out of 685 companies for Interest Coverage. This places Standard Chemical & Pharmaceutical Co in the top 16% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 12.75. Standard Chemical & Pharmaceutical Co's value of 119.64 is 838.4% above this benchmark. Historically, Standard Chemical & Pharmaceutical Co's own Interest Coverage has ranged from 44.28 to 161.01 over the past decade. While the company's 10-year median is 87.70 vs. the industry median of 12.75, Standard Chemical & Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.75, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Standard Chemical & Pharmaceutical Co's current Interest Coverage of 119.64 is 838.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Standard Chemical & Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Standard Chemical & Pharmaceutical Co's current Interest Coverage is 119.64, which is 36% above median its own 10-year median of 87.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Standard Chemical & Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Standard Chemical & Pharmaceutical Co (TPE:1720) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$70.93, compared to a current price of NT$63.90 — trading 9.9% below its estimated fair value. The current Interest Coverage is 119.64, which is 36% above median its 10-year median of 87.70 and 838.4% above the Drug Manufacturers industry median of 12.75. Standard Chemical & Pharmaceutical Co's overall GF Score™ is 95/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Standard Chemical & Pharmaceutical Co (TPE:1720), the current Interest Coverage is 119.64 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Standard Chemical & Pharmaceutical Co (TPE:1720) Overvalued in 2026?
Based on GuruFocus' analysis, Standard Chemical & Pharmaceutical Co stock appears to be undervalued.
The current stock price of NT$63.90 is trading 9.9% below its estimated GF Value™ of NT$70.93.
GuruFocus considers Standard Chemical & Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for TPE:1720:
Interest Coverage: 119.64 (36% above median its 10-year median of 87.70)
GF Value™: NT$70.93 vs. price of NT$63.90 (9.9% below fair value)
Industry Position: 838.4% above the Drug Manufacturers median (#110 of 685)
No single metric tells the full story. See the TPE:1720 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Standard Chemical & Pharmaceutical Co Business Description
Standard Chemical & Pharmaceutical Co Ltd is engaged in the manufacturing and sales of Chinese and western medicine, cosmetics, beverage, normal instruments and medical instruments. Its segments include Medicine, Dietary supplement and Ingredients. The majority of the revenue is derived from the Medicine segment. Geographically it operates in Taiwan, Japan and Others with Taiwan generating the maximum revenue.
95GF Score
Get the complete analysis for TPE:1720
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1720 has been successfully added to your 
